Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.

PURPOSE We sought to determine whether therapy with single-agent fludarabine compared with chlorambucil alone or the combination of both agents had an impact on the incidence and spectrum of infections among a series of previously untreated patients with B-cell chronic lymphocytic leukemia (CLL). PATIENTS AND METHODS Five hundred fifty-four previously untreated CLL patients with intermediate/high-risk Rai-stage disease were enrolled onto an intergroup protocol. Patients were randomized to therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil. Data pertaining to infection were available on 518 patients. Differences in infections among treatment arms were tested with the Kruskal-Wallis, Wilcoxon, and chi(2) tests. RESULTS A total of 1,107 infections (241 major infections) occurred in 518 patients over the infection follow-up period (interval from study entry until either reinstitution of initial therapy, therapy with a second agent, or death). Patients treated with fludarabine plus chlorambucil had more infections than those receiving either single agent (P <.0001). Comparing the two single-agent arms, there were more infections on the fludarabine arm (P =.055) per month of follow-up. Fludarabine therapy was associated with more major infections and more herpesvirus infections compared with chlorambucil (P =.008 and P =.004, respectively). Rai stage and best response to therapy were not associated with infection. A low serum immunoglobulin G was associated with number of infections (P =.02). Age was associated with incidence of major infection in the combination arm (P =.004). CONCLUSION Combination therapy with fludarabine plus chlorambucil resulted in significantly more infections than treatment with either single agent. Patients receiving single-agent fludarabine had more major infections and herpesvirus infections compared with chlorambucil-treated patients.

[1]  E. Montserrat,et al.  Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone , 1985, Cancer.

[2]  L. Bergmann,et al.  Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  B. Cheson.  Infectious and immunosuppressive complications of purine analog therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E. Estey,et al.  Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. , 1993, Leukemia & lymphoma.

[5]  E. Estey,et al.  Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. , 1993, Blood.

[6]  B. Cheson,et al.  Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[7]  M. Talpaz,et al.  Fludarabine therapy in chronic lymphocytic leukemia (CLL). , 1988, Nouvelle revue francaise d'hematologie.

[8]  R. Silver,et al.  A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H. Chapel,et al.  Mechanisms of infection in chronic lymphocytic leukemia. , 1987, Seminars in hematology.

[10]  E. Montserrat,et al.  Serum immunoglobulins in B‐chronic lymphocytic leukemia. Natural history and prognostic significance , 1988, Cancer.

[11]  S. Molica.  Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment. , 1994, Leukemia & lymphoma.

[12]  V. Grégoire,et al.  New initiatives with fludarabine monophosphate in hematologic malignancies. , 1993, Seminars in oncology.

[13]  S. Zeger,et al.  Longitudinal data analysis using generalized linear models , 1986 .

[14]  W. Hiddemann,et al.  Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia , 1996, The Lancet.

[15]  C. Sanders,et al.  Letter to the editor: Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine , 1992, American journal of hematology.

[16]  H. Kantarjian,et al.  Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. , 1988, Leukemia.

[17]  J. Twomey.  Infections complicating multiple myeloma and chronic lymphocytic leukemia. , 1973, Archives of internal medicine.

[18]  E. Anaissie,et al.  Infections in Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine , 1998, Annals of Internal Medicine.

[19]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[20]  P. Wijermans,et al.  Severe immunodeficiency in patients treated with fludarabine monophosphate , 1993, European journal of haematology.

[21]  E. Estey,et al.  Nucleoside analogs in treatment of chronic lymphocytic leukemia. , 1993, Leukemia & lymphoma.

[22]  H. Kantarjian,et al.  Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  E J Freireich,et al.  Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. , 1998, Blood.

[24]  J. Byrd,et al.  Opportunistic pulmonary infections with fludarabine in previously treated patients with low‐grade lymphoid malignancies: A role for pneumocystis carinii pneumonia prophylaxis , 1995, American journal of hematology.

[25]  S. Vadhan-Raj,et al.  Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia. , 1990, The New England journal of medicine.

[26]  H. Helenius,et al.  Infections and serum IgG levels in patients with chronic lymphocytic leukemia , 1992, European journal of haematology.

[27]  E. Anaissie,et al.  Listeriosis in Patients with Chronic Lymphocytic Leukemia Who Were Treated with Fludarabine and Prednisone , 1992, Annals of Internal Medicine.

[28]  B. Coiffier,et al.  Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia. , 1991, European journal of cancer.

[29]  C. Girmenia,et al.  Late listeriosis after fludarabine plus prednisone treatment , 1994, British journal of haematology.

[30]  Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. , 1977 .

[31]  B. Barlogie,et al.  Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. , 1989, Blood.

[32]  E. Smit,et al.  Single-agent oral etoposide for elderly small cell lung cancer patients. , 1990, Seminars in oncology.

[33]  E. Estey,et al.  Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. , 1993, Blood.